|
|
Volumn 20, Issue 18, 2002, Pages 3891-3897
|
|
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACICLOVIR;
ALEMTUZUMAB;
ANTIBODY;
COTRIMOXAZOLE;
FLUDARABINE;
ADULT;
ANTIBODY TITER;
ARTICLE;
CANCER CHEMOTHERAPY;
CANCER REGRESSION;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DISEASE SEVERITY;
DOSE TIME EFFECT RELATION;
DRUG SAFETY;
DYSPNEA;
FEVER;
HUMAN;
HYPOTENSION;
INFECTION PREVENTION;
LYMPHOCYTE COUNT;
LYMPHOCYTE SUBPOPULATION;
LYMPHOCYTOPENIA;
MULTICENTER STUDY;
NAUSEA;
NEUTROPENIA;
OPPORTUNISTIC INFECTION;
PHASE 2 CLINICAL TRIAL;
PNEUMOCYSTIS PNEUMONIA;
PRIORITY JOURNAL;
PROGNOSIS;
RIGOR;
SURVIVAL TIME;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
VOMITING;
ADOLESCENT;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTIGENS, CD;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS;
DNA (CYTOSINE-5-)-METHYLTRANSFERASE;
FEMALE;
HUMANS;
LEUKEMIA, B-CELL, CHRONIC;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
LEUKEMIA, T-CELL, CHRONIC;
MALE;
NEUTROPENIA;
OPPORTUNISTIC INFECTIONS;
PILOT PROJECTS;
REMISSION INDUCTION;
SALVAGE THERAPY;
SURVIVAL RATE;
THROMBOCYTOPENIA;
TREATMENT FAILURE;
TREATMENT OUTCOME;
VIDARABINE;
|
|
EID: 0037106502
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2002.06.119 Document Type: Article |
|
Times cited : (294)
|
|
References (12)
|
